Stifel Financial Corp raised its holdings in Kite Pharma, Inc. (NASDAQ:KITE) by 214.8% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,427 shares of the biopharmaceutical company’s stock after buying an additional 17,350 shares during the period. Stifel Financial Corp’s holdings in Kite Pharma were worth $2,625,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Voya Investment Management LLC raised its stake in Kite Pharma by 30.4% in the second quarter. Voya Investment Management LLC now owns 22,834 shares of the biopharmaceutical company’s stock valued at $2,367,000 after buying an additional 5,327 shares during the period. Dimensional Fund Advisors LP raised its stake in Kite Pharma by 66.1% in the second quarter. Dimensional Fund Advisors LP now owns 110,003 shares of the biopharmaceutical company’s stock valued at $11,404,000 after buying an additional 43,773 shares during the period. ARK Investment Management LLC raised its stake in Kite Pharma by 28.9% in the second quarter. ARK Investment Management LLC now owns 112,645 shares of the biopharmaceutical company’s stock valued at $11,678,000 after buying an additional 25,281 shares during the period. California Public Employees Retirement System raised its stake in Kite Pharma by 2.2% in the second quarter. California Public Employees Retirement System now owns 85,000 shares of the biopharmaceutical company’s stock valued at $8,812,000 after buying an additional 1,800 shares during the period. Finally, Vanguard Group Inc. raised its stake in Kite Pharma by 9.2% in the second quarter. Vanguard Group Inc. now owns 3,998,269 shares of the biopharmaceutical company’s stock valued at $414,501,000 after buying an additional 336,722 shares during the period. Hedge funds and other institutional investors own 87.72% of the company’s stock.

Shares of Kite Pharma, Inc. (NASDAQ:KITE) opened at 179.79 on Friday. The company’s 50-day moving average price is $177.96 and its 200-day moving average price is $114.51. The firm’s market cap is $10.28 billion. Kite Pharma, Inc. has a 12 month low of $39.82 and a 12 month high of $179.95.

Kite Pharma (NASDAQ:KITE) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.97) by $0.03. Kite Pharma had a negative net margin of 1,117.44% and a negative return on equity of 59.56%. The business had revenue of $10.10 million for the quarter, compared to analysts’ expectations of $9.59 million. During the same quarter in the previous year, the firm posted ($0.91) EPS. The business’s revenue for the quarter was up 110.4% compared to the same quarter last year. On average, analysts predict that Kite Pharma, Inc. will post ($8.24) EPS for the current year.

In other Kite Pharma news, Chairman Arie Belldegrun sold 26,347 shares of the business’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $179.66, for a total transaction of $4,733,502.02. Following the sale, the chairman now owns 135,507 shares of the company’s stock, valued at approximately $24,345,187.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Helen Susan Kim sold 26,649 shares of the business’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $109.28, for a total transaction of $2,912,202.72. Following the sale, the executive vice president now directly owns 28,763 shares in the company, valued at approximately $3,143,220.64. The disclosure for this sale can be found here. Insiders have sold a total of 194,785 shares of company stock worth $25,776,870 in the last three months. Insiders own 14.00% of the company’s stock.

Several analysts have issued reports on the company. SunTrust Banks, Inc. lowered Kite Pharma from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. Wedbush upgraded Kite Pharma from an “underperform” rating to a “neutral” rating in a research note on Tuesday, August 29th. BTIG Research lowered Kite Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, August 28th. Jefferies Group LLC restated a “buy” rating and issued a $135.00 price objective (up previously from $121.00) on shares of Kite Pharma in a research note on Wednesday, August 9th. Finally, Cowen and Company reiterated an “outperform” rating on shares of Kite Pharma in a research note on Tuesday, July 4th. Thirteen equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Kite Pharma currently has an average rating of “Hold” and a consensus target price of $94.68.

ILLEGAL ACTIVITY WARNING: This piece was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/kite-pharma-inc-kite-shares-bought-by-stifel-financial-corp/1630168.html.

Kite Pharma Profile

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Want to see what other hedge funds are holding KITE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kite Pharma, Inc. (NASDAQ:KITE).

Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.